New cutoff points of tumor size discriminates patients' survival time more precisely than T classification of the 6th AJCC cancer staging system of breast carcinoma

2008 ◽  
Vol 6 (7) ◽  
pp. 187
Author(s):  
S.H. Kanq ◽  
S.M. Hong ◽  
H. Cho ◽  
B.Y. Choi ◽  
S.J. Lee ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Survival Time ◽  
Tumor Size ◽  
Staging System ◽  
Cancer Staging ◽  
Cutoff Points ◽  
T Classification

Molecular validation of the 8th edition AJCC cancer staging system in patients with resected pancreatic cancer: Proposal of integrative translational staging system.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16765-e16765
Author(s):  
Sung Hwan Lee ◽  
Sunyoung S. Lee ◽  
Ju-Seog Lee
Keyword(s):  
Pancreatic Cancer ◽  
Tumor Size ◽  
Optimal Algorithm ◽  
Unmet Need ◽  
Staging System ◽  
Cancer Staging ◽  
Clinical Staging ◽  
Mesenchymal Transition ◽  
Molecular Features ◽  
8Th Edition

e16765 Background: Even though the 8th edition AJCC cancer staging system for pancreatic cancer has validated with major clinicopathologic factors in multiple clinical cohorts, there is still an unmet need for integrative consideration using multi-omics data to stratify the patients with pancreatic cancer elaborately. Methods: We performed a comprehensive analysis and profiling using genomic, transcriptomic, and proteomic data from TCGA-PAAD and other translational cohorts (4 cohorts, n = 340). Molecular features and major subtypes were analyzed mutually with clinical and pathologic factors, especially the 8th AJCC staging system. Results: Aggressive molecular subtypes, basal-like and squamous subtype, were significantly associated with a higher nodal stage, but tumor size didn't show a clear association with molecular features. The activated stroma of pancreatic cancer microenvironment was significantly correlated with poor differentiation and large tumor size. The mutational pattern of KRAS and several transcriptomic pathways such as eptihelial-mesenchymal transition and DNA repair were differently presented in each clinical stage from the 8th AJCC TNM staging system. The optimal algorithm was identified to show significantly higher performance for the prediction for cancer relapse and cancer-specific survival in discovery and validation cohorts. The in silico prediction for molecular target agents and immunotherapy were performed for final clusters from optimal stratification system revealed from the integrative analysis. Conclusions: Our comprehensive multi-omics analysis reveals clear needs for the combination of clinical staging and molecular profiling and provides crucial evidence for precision strategy in patients with resectable pancreatic cancer.

scholarly journals Evolution of Classification of Thymic Epithelial Tumors in the Era of Dr Thomas V. Colby

2017 ◽  
Vol 141 (2) ◽  
pp. 232-246 ◽  
Author(s):  
Anja C. Roden
Keyword(s):  
Prognostic Significance ◽  
Staging System ◽  
Cancer Staging ◽  
World Health ◽  
Thymic Epithelial Tumors ◽  
Epithelial Tumors ◽  
New Concepts ◽  
Prognostic Implications ◽  
Health Organization

Context.—Numerous histomorphologic and staging classifications of thymic epithelial tumors (TETs) have been proposed during the last century, suggesting that the classification of these tumors is challenging and controversial. Difficulties of classifying TETs include various combinations of epithelial cells and lymphocytes and the paucity of these tumors. The prognostic significance, specifically of the histomorphologic classifications, has been debated. Early classifications were also challenged by the uncertainty of the neoplastic component(s) of the tumor.Objective.—To discuss the evolution of the histomorphologic classification and the staging system of TET. Controversies and problems of some classifications and their importance for therapeutic management and prognosis will be reviewed. Classifications that incorporated new concepts and approaches at the time or outcome studies will be highlighted. Current classifications will be discussed and the staging system that was recently proposed for the upcoming eighth American Joint Committee on Cancer staging will be described.Data Sources.—Search of literature database (PubMed) and current (2015) World Health Organization classification.Conclusions.—Histomorphologic and staging classifications of TET have evolved during the last century and especially during the era of Thomas V. Colby, MD. Evidence supports that the staging system has prognostic implications independent of and superior to the histomorphologic classification. Histomorphology appears to be important for biologic features of TET.

Eyelid sebaceous gland carcinoma: An assessment of the T classification of the American Joint Committee of Cancer TNM staging system 8th versus 7th edition

2020 ◽  
pp. 112067212093648
Author(s):  
Fatimah AlHammad ◽  
Deepak P Edward ◽  
Hind M Alkatan ◽  
Sahar Elkhamary ◽  
Adriana Iuliano ◽  
...  
Keyword(s):  
Sebaceous Gland ◽  
Staging System ◽  
Nodal Metastasis ◽  
Sebaceous Gland Carcinoma ◽  
7Th Edition ◽  
Poor Tumor Differentiation ◽  
Gland Carcinoma ◽  
T Classification ◽  
8Th Edition

Purpose: To assess the prognostic values of the T classification of the 8th edition of the American Joint Committee of Cancer staging system and compare it to the 7th edition. Methods: Multicenter retrospective study of patients with eyelid sebaceous gland carcinoma. The primary outcome measure was the differences between outcomes when tumors were staged with either 7th or 8th edition. The measures evaluated included presenting features, management, histopathology, metastasis, recurrence, and mortality. Results: Of the 60 patients (median age 73 years), 31 (51.7%) were females. A change in T staging occurred in 39 patients (65%) when the 8th edition was applied. Advanced categories (T3/T4) were significantly associated with nodal metastasis ( p = 0.037) using the 8th edition criteria but not with the 7th edition ( p = 0.066). The 8th edition T categorization significantly correlated with eye survival ( p = 0.022) while the 7th edition did not ( p = 0.058). Applying the 8th edition, category T4 at presentation was associated with a higher risk of nodal metastasis ( p = 0.037) but not associated with local recurrence, distant metastasis, or tumor-related death ( p = 0.281, p = 0.737, p = 0.319, respectively). T3/T4 category tumors were significantly associated with poor tumor differentiation ( p = 0.001), and papillary histologic pattern ( p = 0.024) but not with pagetoid spread ( p = 0.056). Conclusion: The application of the 8th edition AJCC staging system for eyelid SGC may accurately predict nodal metastasis. Local recurrence and distant metastasis were not significantly associated with T classification, using either edition. Poor tumor differentiation and papillary pattern were associated with T3/T4 categories suggesting that pathological features may assist in determining prognosis.

Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system

2019 ◽  
Vol 94 (2) ◽  
pp. 284-289 ◽  
Author(s):  
Yasuhiro Fujisawa ◽  
Shusuke Yoshikawa ◽  
Akane Minagawa ◽  
Tatsuya Takenouchi ◽  
Kenji Yokota ◽  
...  
Keyword(s):  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition ◽  
Study Database

Importance of subset classification based on tumor size for patients with single hepatocellular carcinoma.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 373-373
Author(s):  
Jian-Hong Zhong ◽  
Bang-De Xiang ◽  
Liang Ma ◽  
Yan-Yan Wang ◽  
Ning-Fu Peng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Tumor Size ◽  
Staging System ◽  
Cancer Staging ◽  
Group 4 ◽  
Group 3 ◽  
Group 2 ◽  
Similar Survival ◽  
Group 1

373 Background: Single hepatocellular carcinoma (HCC) regardless of size that without vascular invasion is classified as stage A disease in the Barcelona Clinic Liver Cancer staging system. However, patients with different tumor size may have different overall survival after hepatectomy. This study compared the prognosis of patients with single HCC after hepatectomy among groups with different tumor size. Methods: Patients with newly diagnosed single HCC from January 1, 2004 to October 31, 2013 were classified according to tumor size: group 1, ≤ 5 cm; group 2, > 5 cm and ≤ 8 cm; group 3, > 8 cm and < 10 cm; and group 4, ≥ 10 cm. Overall survival analysis was performed according to tumor size. Results: A total of 857 patients were enrolled. Among them, 814 (95.0%) were with Child-Pugh A class liver function. Blood loss was 367 ± 424 mL. Groups 1, 2, 3, and 4 consisted of 426 (49.7%), 229 (26.7%), 52 (6.1%), and 150 (17.5%) patients, respectively. The 5 years overall survival ranged from 35 to 63% in all four groups. The median survival time differed significantly according to tumor size (76, 49, 43, and 38 months in groups 1, 2, 3, and 4, respectively; P  <  0.001). Group 3 had overall similar survival to group 4. Multivariate analysis showed that group 3 and 4 had significantly worse overall survival compared to group 1 and 2. Conclusions: Patients in group 3 and 4 had significant worse prognosis than those in group 1 or group 2. Our results suggest that subset classification based on tumor size is warranted to patients’ prognosis.

scholarly journals Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bin-yong Liang ◽  
Jin Gu ◽  
Min Xiong ◽  
Er-lei Zhang ◽  
Zun-yi Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Size ◽  
Staging System ◽  
Prognostic Impact ◽  
Term Survival ◽  
Long Term Survival ◽  
Before And After ◽  
Cirrhotic Patients ◽  
Curative Hepatectomy

AbstractHepatocellular carcinoma (HCC) is usually associated with varying degrees of cirrhosis. Among cirrhotic patients with solitary HCC in the absence of macro-vascular invasion, whether tumor size drives prognosis or not after hepatectomy remains unknown. This study aimed to investigate the prognostic impact of tumor size on long-term outcomes after hepatectomy for solitary HCC patients with cirrhosis and without macrovascular invasion. A total of 813 cirrhotic patients who underwent curative hepatectomy for solitary HCC and without macrovascular invasion between 2001 and 2014 were retrospectively studied. We set 5 cm as the tumor cut-off value. Propensity score matching (PSM) was performed to minimize the influence of potential confounders including cirrhotic severity that was histologically assessed according to the Laennec staging system. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups before and after PSM. Overall, 464 patients had tumor size ≤ 5 cm, and 349 had tumor size > 5 cm. The 5-year RFS and OS rates were 38.3% and 61.5% in the  ≤ 5 cm group, compared with 25.1% and 59.9% in the > 5 cm group. Long-term survival outcomes were significantly worse as tumor size increased. Multivariate analysis indicated that tumor size > 5 cm was an independent risk factor for tumor recurrence and long-term survival. These results were further confirmed in the PSM cohort of 235 pairs of patients. In cirrhotic patients with solitary HCC and without macrovascular invasion, tumor size may significantly affect the prognosis after curative hepatectomy.

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 ◽  
Vol 19 (16) ◽  
pp. 3635-3648 ◽  
Author(s):  
Charles M. Balch ◽  
Antonio C. Buzaid ◽  
Seng-Jaw Soong ◽  
Michael B. Atkins ◽  
Natale Cascinelli ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Elevated Serum ◽  
Primary Melanoma ◽  
Staging System ◽  
Distant Metastases ◽  
Lactic Dehydrogenase ◽  
Cancer Staging ◽  
Sixth Edition ◽  
Stage Grouping ◽  
American Joint Committee

PURPOSE: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS: The prognostic factors analysis described in the companion publication (this issue), as well as evidence from the published literature, was used to assemble the tumor-node-metastasis criteria and stage grouping for the melanoma staging system. RESULTS: Major changes include (1) melanoma thickness and ulceration but not level of invasion to be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, microscopic) versus clinically apparent (ie, macroscopic) nodal metastases to be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase to be used in the M category; (4) an upstaging of all patients with stage I, II, and III disease when a primary melanoma is ulcerated; (5) a merging of satellite metastases around a primary melanoma and in-transit metastases into a single staging entity that is grouped into stage III disease; and (6) a new convention for defining clinical and pathologic staging so as to take into account the staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. CONCLUSION: This revision will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.

Sign in / Sign up

Export Citation Format

Share Document